Healius Limited · ASX:HLS
Healius — Shareholder Meeting (October 2026)
6 slides from Healius's shareholder meeting presentation, Oct 22, 2026
Slide 1: 2026 Annual General Meeting
rsonal use only 2026 Annual General Meeting Thursday, 22 October 2026 Swissotel, Sydney
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain forward-looking statements regarding Healius Limited’s financial performance, guidance and business prospects. rsonal use only These statements are subject to risks and uncertainties, many beyond the company’s control and are based on manageme
Slide 3: CEO Presentation
rsonal use only CEO Presentation Paul Anderson Healius Managing Director & Chief Executive Officer
Slide 4: Pathology is the quiet engine of evidence-based care
Pathology is the quiet engine of evidence-based care rsonal use only Pathology enables early diagnosis and timely intervention 70% of medical treatment decisions and 100% of cancer diagnoses rely on pathology Pathology data can provide unparalleled insights into the nation’s health 4 Healius Limited
Slide 5: T27 Scorecard – Performance Update FY26
T27 Scorecard – Performance Update FY26 Our aim is to deliver mid-to-high single-digit EBIT margins by December 2028 ✓ Delivery complete ▸ Partially delivered > On track ✓• Collections: >80% of ACC episodes now processed through Medway Collections ▸• Collections: New HubSpot CRM capability implement
Slide 6: The role of pathology in prevention
The role of pathology in prevention We believe we have a broader role to play in supporting better health outcomes for Australians through information and awareness Women & Cardiovascular rsonal use only Diabetes Watch Report Health Misinformation Research Update Disease in Australia November 2025 F